Sort
Categories
- #EMSPVirtual2021
- Associate members
- Document
- EMSP Events
- EMSP Events|EMSP News
- EMSP News
- EMSP News|From Europe
- EMSP News|From Europe|Stakeholder Events
- EMSP News|MS Research
- EMSP News|Press Releases
- EMSP News|Young People with MS
- From Europe
- From Europe|Member News
- From Europe|Stakeholder Events
- From Europe|Young People with MS
- Full members
- Full members|Member News
- Member News
- Member News|Young People with MS
- MS Research
- News – EMSP
- Press Releases
- Stakeholder Events
- Uncategorized
- Young People with MS
Impact of Multiple Sclerosis Symptoms (IMSS) Survey Now Live!
We are pleased to announce that the Impact of Multiple Sclerosis Symptoms (IMSS) survey is now officially live! Why is…
EMSP joins new EU funded project called More-EUROPA
While randomized controlled trials (RCTs) remain the mainstay in drug development, approval, and reimbursement, the potential of real-world data (RWD)…
MS Hive – a new opportunity for young creatives
EMSP is delighted to announce the launch of the MS Hive, an initiative for young creatives to develop their own…
Paediatric MS: Our Recommendations for Caregivers
Multiple Sclerosis was once considered a disease occurring exclusively in adulthood, however, there is growing recognition that MS can be…
HTx – Next Generation Health Technology Assessment
How to decide on the best standard of care for a person with MS? What if patients could contribute to…
Nose-to-Brain-Patch Final Outcomes
Effective drugs for the treatment of diseases of the central nervous system such as multiple sclerosis do exist. However, the…